Nocardiosis

Back

Background

Nocardiosis is an infectious disease caused by various aerobic soil saprophytes of the gram-positive bacilli genus Nocardia.[1, 2] It can present as acute, subacute, or chronic infections, often in cutaneous, pulmonary, or disseminated forms. The disease is characterized by suppurative or granulomatous infections, with pneumonia being the most typical manifestation. Skin and central nervous system infections are also common.

Nocardia species, such as N asteroides and N brasiliensis, are primarily responsible for human infections. N asteroides usually leads to pulmonary and disseminated infections, whereas N brasiliensis is more associated with skin infections, particularly in tropical climates. Infection occurs through inhalation of dust containing the bacteria or direct inoculation via cuts or scrapes when contaminated soil or water enters the body.

Nocardiosis can affect individuals of all ages, but the incidence is higher among older adults, especially men, and those who are immunocompromised. Person-to-person transmission is rare. Diagnosis typically is made through culture and special stains, and treatment usually involves sulfonamides.

Primary cutaneous nocardiosis may present as cellulitis, abscesses, or lymphocutaneous infections, whereas pleuropulmonary nocardiosis manifests as pneumonitis, primarily in immunocompromised hosts. Disseminated nocardiosis can affect any organ, with brain and meninges lesions being the most common. Nocardia commonly is found in standing water, decaying plants, and soil, contributing to its potential for infection.

Pathophysiology

Members of the genus Nocardia are aerobic actinomycetes that are ubiquitous saprophytes in soil, decaying organic matter, and fresh and salt water. Over 100 species of the genus Nocardia have been identified, more than half of which have been described since the early 2000s.

The taxonomy has been challenging and likely remains in evolution.[3, 4] Most human infections are due to members of the formerly called Nocardia asteroides complex. N asteroides complex was later separated into Nocardia abscessus, Nocardia brevicatena-paucivorans complex , Nocardia nova complex, Nocardia transvalensis complex, Nocardia farcinica, Nocardia asteroides sensu stricto, and Nocardia cyriacigeorgica; however, use of the term "N asteroides complex" is outdated because of the heterogenous group of organisms it includes. Nocardia species also cause infections in animals, including bovine mastitis and sporotrichoid nocardiosis in horses.

When observed microscopically, either in Gram-stained smears of clinical specimens or cultures or on histopathology in tissues, Nocardia organisms are delicate, branching, beaded, filamentous, gram-positive bacteria with a characteristic morphology to a trained observer. 



View Image

High-power microscopic appearance of Nocardia. Image courtesy of CDC.

Nocardia are typically weakly acid-fast after traditional staining and positive on modified acid-fast staining, but this is not invariable.

The cutaneous, lymphocutaneous, and subcutaneous forms of nocardiosis arise from local traumatic inoculation. These infections are not necessarily associated with immunocompromised host states, but dissemination from these sites of inoculation is more likely in immunocompromised hosts, particularly those with impaired cell-mediated immunity.[5]  Pleuropulmonary nocardiosis presumably arises from inhalation exposure. Disseminated nocardiosis results from hematogenous dissemination, usually from a pulmonary focus. Most persons with disseminated nocardiosis have underlying immunocompromising disease or are receiving immunosuppressive therapy.

Nocardiosis produces suppurative necrosis with frequent abscess formation at sites of infection. 



View Image

Photomicrograph of tissue biopsy stained with Gomori methenamine silver demonstrating acute inflammatory response and organisms compatible with Nocard....

Disease manifestations of nocardiosis are determined by strain characteristics, inoculation site, tissue tropism, ability to survive initial neutrophilic leukocyte phagocytic attack, and the nature of the immune response. T-cell–mediated immunity is the principal protective immune response to nocardiosis.[5] Therefore, nocardiosis is most problematic in individuals with impaired T-cell–mediated immunity.[4]

Epidemiology

Frequency

United States

The estimated incidence of nocardiosis in the United States is 500-1000 cases per year.[2]

Clusters of nocardiosis have been described in hospitalized patients, related to contaminated fomites from construction or contaminated hands of staff.

International

No reliable estimates on the international frequency of nocardiosis are available.

Mortality/Morbidity

Nocardiosis has a variable prognosis, depending on the site of infection, extent of infection, and underlying host factors.[6]

Cure rates with appropriate therapy are approximately 100% in skin and soft-tissue infections.

Up to 90% percent of pleuropulmonary infections can be cured with appropriate therapy.

The cure rate in disseminated nocardiosis falls to 63%, while only half of the patients with brain abscess can be cured with therapy.[7]

Race

Nocardiosis has no apparent racial predilection.

Sex

Nocardiosis is more common in males than in females, with a male-to-female ratio of 3:1. This difference is likely related to exposure frequency rather than a gender difference in susceptibility.

Age

All ages are susceptible to nocardiosis. The mean age at diagnosis is in the fourth decade of life.

Prognosis

The one-year rate for all-cause mortality from nocardiosis in both immunocompetent and immunocompromised patients has been found to be 19-22%.[8, 9]  Poor prognostic factors in nocardiosis patients are ​Nocardia CNS infections, recipients of solid-organ transplants, HIV/AIDS with advanced immunocompromised state, delayed diagnosis, and premature discontinuation of antimicrobial therapy.[9, 10]

Patient Education

Patients with nocardiosis must be educated about the need for protracted antimicrobial therapy.

Patients with nocardiosis should be informed of the potential adverse effects of protracted antimicrobial therapy and which circumstances require reporting to their physician promptly.

History

Clinical manifestations of nocardiosis depend on the site of infection.[11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]

Pulmonary disease is the predominant clinical finding in most patients with nocardiosis.[14, 22, 8]  ​Pulmonary nocardiosis may be acute, subacute, or chronic. Clinical manifestations include inflammatory endobronchial masses or localized or diffuse pneumonia, which may be accompanied by cavitation, abscess formation, pleural effusion, or empyema. Symptoms in patients with nocardiosis are indistinguishable from those in patients with similar pulmonary infections of other microbial etiology. Cough with sputum production and fever are the dominant symptoms. At least 40% of patients with disseminated nocardiosis have a pulmonary infection; therefore, the clinical presentation may be dominated by the pulmonary symptoms.

Primary cutaneous nocardiosis can present as cutaneous infection, lymphocutaneous infection, or subcutaneous infection. Cutaneous nocardiosis generally manifests as either cellulitis or, more likely, single or multiple non-tender erythematous nodule(s) at the site of traumatic inoculation.[25]  These nodules occasionally drain purulent material. Lymphocutaneous nocardiosis manifests as similar lesions accompanied by ascending regional lymphadenopathy. The lymphadenopathy may also occasionally drain purulent material. N brasiliensis is the most common cause of progressive cutaneous and lymphocutaneous (sporotrichoid) disease.[26, 27, 28]

Patients with nocardiosis may present with deep abscesses at any site, particularly in the lower extremities or the CNS. In patients with extra-CNS abscesses, fever and local symptoms predominate. Up to 20% of reported nocardiosis cases and 44% of disseminated nocardiosis cases involve the CNS.[5] When occurring in isolation, CNS nocardiosis manifests as a slowly progressive mass lesion, with a host of specific neurologic findings related to the specific location of the abscess. CNS nocardiosis is detected in up to 44% of disseminated nocardial infections.[5, 29]  In two-thirds of patients with CNS nocardiosis, clinical findings indicate abscess with or without meningitis, including fever, headache, stiff neck, and/or altered mental status.

Nocardial species can cause mycetoma, a chronic, swollen, purulence-draining, subcutaneous infection of the extremities, typically encountered in tropical areas of the world, but also has been reported from the southern United States, Central, and South Americas, and Australia. It is usually ascribed to N brasiliensis.[17, 21]

Cases of traumatic inoculation or postoperative nocardial keratitis and endophthalmitis have been well described.[30, 31, 32, 33]

Postoperative wound infections due to Nocardia species are rare, but case clusters of nosocomial transmission have been described.[34]

Traumatic inoculation nocardial arthritis has occurred but is rare. This presents as a subacute or chronic monoarthritis, typically involving the knee.

Risk Factors

Pulmonary and disseminated nocardiosis are clearly associated with immunocompromising conditions, with approximately 60% of cases of nocardiosis other than mycetoma occurring in individuals with some compromise of host defense systems. Conditions associated with an increased risk of pulmonary and disseminated nocardiosis include the following[1, 2] :

Physical Examination

The physical findings of nocardiosis also vary based on the site of infection.

Patients with primary cutaneous nocardiosis present with cellulitis, cutaneous nodules, nodules with ascending lymphadenopathy, or with a mycetoma can be clinically indistinguishable from similar infections due to other pathogens.

Patients with pulmonary nocardiosis present with findings of pulmonary consolidation with or without evidence of pleural effusions.

The presentation of disseminated nocardiosis depends on the sites of infection. Pulmonary findings frequently predominate. Local findings associated with metastatic abscesses may be present at almost any site but are typically in the lower extremities. The combination of pneumonia and lower-extremity abscess is not specific to but particularly suggestive of nocardiosis. Patients with brain abscess may present with altered mental status, personality changes, or various localizing neurologic findings. Patients with meningitis present with fever, altered consciousness, and meningismus.

Laboratory Studies

The diagnosis of nocardiosis is established with culture of the causative organism from the infection site(s). Since nocardiae grow slower than common bacteria, the microbiology laboratory should always be notified when nocardiosis is clinically suspected. This is particularly true when sputum is the submitted specimen. Respiratory secretions, skin biopsy samples, and aspirates from abscesses are the most common specimens from which Nocardia species are identified. Direct smears or histopathologic stains of these specimens can be highly suspicious, as noted above. Nocardia species can usually be isolated in 3-5 days. Isolation of Nocardia sp. from cutlures represents true infection as this organism is not considered to be a colonizing organism.  

Blood cultures are positive for Nocardia organisms in a minority of patients, but they always should be obtained when pulmonary or disseminated nocardiosis is suspected.

Immunodominant antigens of Nocardia species have been identified and used in serological assays. However, no serologic technique or molecular technique is yet available for routine clinical use. Similarly, nucleic acid amplification assays have been described but are not available for routine clinical use.

Polymerase chain reaction (PCR) of 16s rRNA has been determined a sensitive and specific technique for detection and species-level identification of Nocardia.[37]  

Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) has also been studied for Nocardia species identification, and the efficacy of MALDI-TOF technology relies on future expansion of database libraries.[38]   

Imaging Studies

Plain chest radiography and, often, CT chest scanning are useful in evaluating pulmonary nocardiosis and in monitoring the course of the infection. However, no characteristic radiographic findings have been described. Radiographic findings may include irregular nodules (which may cavitate), reticulonodular or diffuse alveolar pulmonary infiltrates, lung abscess formation, and pleural effusion. 



View Image

Plain chest radiograph in a patient with nocardiosis. Image courtesy of Applied Radiology, Anderson Publishing, LTD.



View Image

Chest CT scan in a patient with pleuropulmonary nocardiosis. Image courtesy of Applied Radiology, Anderson Publishing, LTD.

All patients with nocardiosis, except those with mycetoma, should undergo brain imaging with either CT scanning or MRI (likely preferred). Intracranial abscess is the most common abnormality found. Spread of intracranial abscesses to contiguous structures is particularly suggestive of nocardiosis. 



View Image

Brain CT scan in a patient with nocardial brain abscess. Image courtesy of Applied Radiology, Anderson Publishing, LTD.

Localized symptoms other than pulmonary or CNS should be evaluated with appropriate site-specific imaging.

Other Tests

If meningitis is suspected, cerebrospinal fluid (CSF) should be obtained for analysis unless this is contraindicated by mass effect on brain imaging. Nocardial meningitis typically results in findings typical of bacterial meningitis (ie, neutrophilic pleocytosis, hypoglycorrhachia, and an elevated CSF protein level).

Procedures

Biopsy of skin lesions or aspiration of deep abscesses may be required for diagnosis of nocardiosis.

Similarly, in patients with pulmonary nocardiosis, bronchoalveolar lavage and/or transbronchial lung biopsy may be required if the microbial etiology is not definitively established based on examination and culture of expectorated sputum.

Histologic Findings

Suppurative infection with organisms of characteristic morphology and staining attributes is the typical histopathologic finding in nocardiosis. Granulomatous infection is occasionally encountered.

Approach Considerations

Nocardiosis treatment typically involves trimethoprim/sulfamethoxazole (TMP/SMX) or high doses of sulfonamides, with the need to maintain specific blood concentrations due to the slow response.[1, 2] In immunocompromised patients or those with disseminated disease, TMP/SMX may be combined with other antibiotics until further testing is completed. Alternatives are available for those with sulfonamide hypersensitivity or refractory infections. Localized abscesses generally require incision, drainage, and surgical debridement.

 

 

 

 

Medical Care

Protracted specific antimicrobial therapy is the mainstay of medical care for nocardiosis. Therapy is generally recommended for at least 6 months, and at least 12 months for CNS infections.[3, 17]

In patients who require immunosuppressive therapy, such therapy can generally be continued while appropriate specific therapy for nocardiosis is administered.

For the treatment of nocardiosis, trimethoprim/sulfamethoxazole (TMP/SMX) is administered at a dosage of 15 mg/kg/day (of the TMP component) orally every 6 to 12 hours, or high doses of a sulfonamide such as sulfadiazine (1 g orally every 4 to 6 hours).[1]  Due to the slow response in most cases, it is essential to maintain a sulfonamide blood concentration of 12 to 15 mg/dL 2 hours after the last dose for an extended period. The treatment duration varies based on the type of infection and the patient's risk factors. In immunocompromised patients or those with disseminated disease, TMP/SMX should be combined with amikacin, imipenem, or meropenem until species identification and susceptibility testing are completed.

If there is sulfonamide hypersensitivity or a refractory infection, alternative treatments include amikacin, tetracyclines (especially minocycline), imipenem/cilastatin, meropenem, ceftriaxone, cefotaxime, extended-spectrum fluoroquinolones (like moxifloxacin), or dapsone, with tigecycline as a potential option. The choice of alternative antibiotics should be guided by in vitro susceptibility data.

Localized abscesses typically require incision, drainage, and surgical debridement.

 

Surgical Care

For lesions outside the CNS, surgical management is the same as standard recommendations for other infections; that is, localized abscesses generally require prompt surgical therapy. Pericarditis complicating pulmonary infection may be fatal and requires surgical drainage.[32]

In patients with nocardial brain abscesses, surgery should be performed if the lesions are large, readily accessible, or progressing beyond 2 weeks of antimicrobial therapy.[15]

Consultations

An infectious diseases specialist is recommended for coordinating protracted antimicrobial therapy. Depending on the infection site(s), consultation with a pulmonologist, thoracic surgeon, general surgeon, and/or neurosurgeon may be appropriate.

Diet

No specific dietary recommendations are warranted.

Activity

Activity can be as tolerated by the patient.

Prevention

Primary prevention is not routinely recommended for immunosuppressed individuals.

Patients at risk of Nocardia infection should be evaluated for reduction or cessation of immunosuppressive therapy. In patients with prior nocardiosis infections on immunosuppressive therapy which cannot be discontinued, secondary prophylaxis may be considered with daily double-strength trimethoprim-sulfamethoxazole (TMP-SMX).[39, 40]

While lower dose regimens of TMP-SMX are effective in preventing other opportunistic infections, such as Pneumocystis jiroveci pneumonia (PJP) (See the Medscape Reference article Preventing Opportunistic Infections in Patients With HIV) in immunocompromised patients, bi-and tri-weekly TMP-SMX regimens have not been sufficient in preventing Nocardia in high-risk patients.[39, 41]

Long-Term Monitoring

Antimicrobial therapy for pulmonary or disseminated nocardiosis should be continued for 6-12 months and at least 1 month following resolution of all evidence of infection.[1, 2] Patients should undergo follow-up monthly after discharge from the hospital and during antimicrobial therapy to ensure an appropriate response to therapy and monitor for medication adverse effects with laboratory studies. These patients require at least 12 months of monitoring after the completion of therapy to detect possible late relapses.

Follow-up radiographic studies should be obtained roughly every 3 months to monitor treatment. Examples include chest radiographs and CT-scans for patients with pulmonary disease and CT-brain or MRI for CNS disease. Radiographic studies are required after antimicrobial therapy has concluded to to ensure there is not evidence of relpase on imaging. 

 

Medication Summary

General treatment guidelines for nocardiosis are hindered by (1) lack of controlled clinical trials of therapy; (2) difficult, and, in the past, poorly standardized in vitro susceptibility testing leading to widely disparate reports of in vitro antimicrobial susceptibility[42, 43] ; (3) lack of firm data on the correlation of in vitro susceptibility with in vivo therapeutic efficacy; and (4) the changing taxonomy of Nocardia species. Various species of Nocardia have different antimicrobial susceptibility patterns, N farcinica has high rates of resistnace to numeous antibiotics. Therapy should guided by in vitro susceptibility testing at a specialized laboratory experienced at testing Nocardia strains.

Sulfonamides have long been the first-line antimicrobial therapy for nocardiosis. Among the sulfonamides, sulfadiazine is generally preferred because of its CNS and CSF penetration. Although not convincingly demonstrated superior, trimethoprim-sulfamethoxazole (TMP-SMX) is considered the therapy of choice by most authorities. Divided doses of 5-10 mg/kg/d of the trimethoprim (TMP) component should be administered in mild-moderate pulmonary infections in immunocompetent patients. Divided dosing of 10-15 mg/kg of the TMP component should be required in immunocompromised patients with mild-moderate pulmonary infecton and with CNS infection. Patients with sulfa allergy should be densensitized if possible. Dosing of trimethoprim-sulmamethoxazole requires adjustment with renal insufficiency. 

Additional parenteral therapies include carbapenems (imipenem or meropenem, but not ertapenem), third-generation cephalosporins (cefotaxime or ceftriaxone), and amikacin, alone or in combination. Imipenem plus amikacin may be the preferred regimen in sulfonamide-allergic individuals. Linezolid in vitro activity and in vivo efficacy has been reported.[44] Tigecycline also has reported activity in vitro.[3]

For most serious Nocardia infections, combination therapy has been recommended with at least IV agents.[3] Combination therapy should be continued until clinical improvement occurs and confirmation of in vitro drug susceptibility has been acquired. Typically 3-6 weeks of induction therapy with IV antibiotics are necessary for severe infeciton until patients can be switched to oral antibiotic therapy. 

Oral antibiotic therapies include minocycline, amoxicillin/clavulanate and linezolid. These may be used initially in mild-to-moderately severe disease or as sequential therapy after an induction course of parenteral therapy. Modern fluoroquinolones often have demonstrable in vitro activity against Nocardia species but have failed therapeutically. Clarithromycin may have activity against Nocardia nova. Guidance regarding which oral antibiotics to are effective depends of susceptibility testing. 

Duration of treatment is generally prolonged to minimize risk of disease relapse. Immunocompetent patients with non-CNS nocardiosis may be successfully treated with 3-6 months of antimicrobial therapy. All immunosuppressed patients and those with CNS disease should receive 12 months of therapy or longer if escalation of immunosuppression takes place (such as graft or organ rejections). For patients on chronic steroid or cytotoxic therapy, prolonged maintenance of anti-nocardial therapy may be indicated. Appropriate clinical monitoring should be conducted during protracted antimicrobial therapy.[3]

Sulfadiazine (Microsulfon)

Clinical Context:  Exerts its bacteriostatic action by competitive antagonism of paraaminobenzoic acid (PABA). Microorganisms that require exogenous folic acid and do not synthesize folic acid are not susceptible to the action of sulfonamides. In difficult cases, may be important to document peak serum levels (2 h after PO dose are 100-150 mg/L).

Trimethoprim-sulfamethoxazole (Bactrim, Septra)

Clinical Context:  Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid.

Meropenem (Merrem IV)

Clinical Context:  Bactericidal broad-spectrum carbapenem antibiotic that inhibits cell-wall synthesis. Effective against most gram-positive and gram-negative bacteria. Has slightly increased activity against gram-negative organisms and slightly decreased activity against staphylococci and streptococci compared to imipenem.

Cefotaxime (Claforan)

Clinical Context:  Third-generation cephalosporin with gram-negative spectrum. Lower efficacy against gram-positive organisms. Arrests bacterial cell wall synthesis, which in turn inhibits bacterial growth.

Ceftriaxone (Rocephin)

Clinical Context:  Third-generation cephalosporin with broad-spectrum, gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms. Arrests bacterial growth by binding to one or more penicillin-binding proteins.

Amikacin (Amikin)

Clinical Context:  For gram-negative bacterial coverage of infections resistant to gentamicin and tobramycin. Effective against Pseudomonas aeruginosa.

Irreversibly binds to 30S subunit of bacterial ribosomes and blocks recognition step in protein synthesis, which causes growth inhibition. Use patient's IBW for dosage calculation.

Minocycline (Minocin)

Clinical Context:  Treats infections caused by susceptible gram-negative and gram-positive organisms, in addition to infections caused by susceptible Chlamydia, Rickettsia, and Mycoplasma.

Amoxicillin and clavulanate (Augmentin)

Clinical Context:  Drug combination treats bacteria resistant to beta-lactam antibiotics. In children >3 mo, base dosing protocol on amoxicillin content. Because of different amoxicillin/clavulanic acid ratios in 250-mg tab (250/125) vs 250-mg chewable tab (250/62.5), do not use 250-mg tab until child weighs >40 kg.

Linezolid (Zyvox)

Clinical Context:  Prevents formation of functional 70S initiation complex, which is essential for bacterial translation process. Bacteriostatic against enterococci and staphylococci and bactericidal against most strains of streptococci. Used as alternative in patients allergic to vancomycin and for treatment of vancomycin-resistant enterococci.

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

What is nocardiosis?What is the pathophysiology of nocardiosis?What is the prevalence of nocardiosis in the US?What is the global prevalence of nocardiosis?What is the prognosis of nocardiosis?What are the racial predilections of nocardiosis?What are the sexual predilections of nocardiosis?Which age groups have the highest prevalence of nocardiosis?What is included in patient education about nocardiosis?Which clinical history findings are characteristics of nocardiosis?Which physical findings are characteristic of nocardiosis?Which conditions increase the risk for pulmonary and disseminated nocardiosis?What are the differential diagnoses for Nocardiosis?What is the role of lab studies in the diagnosis of nocardiosis?What is the role of imaging studies in the diagnosis of nocardiosis?What is the role of CSF analysis in the diagnosis of nocardiosis?What is the role of biopsy in the diagnosis of nocardiosis?Which histologic findings are characteristic of nocardiosis?How is nocardiosis treated?What is the role of surgery in the treatment of nocardiosis?Which specialist consultations are beneficial to patients with nocardiosis?Which dietary modifications are used in the treatment of nocardiosis?Which activity modifications are used in the treatment of nocardiosis?How is nocardiosis prevented?What is included in the long-term monitoring of patients with nocardiosis?What is the role of medications in the treatment of nocardiosis?Which medications in the drug class Antibiotics are used in the treatment of Nocardiosis?

Author

Shirin A Mazumder, MD, FIDSA, Associate Professor of Medicine, Director of Infectious Disease Fellowship Program, Division of Infectious Diseases, Department of Internal Medicine, University of Tennessee Health Science Center College of Medicine, University of Tennessee Methodist Physicians

Disclosure: Nothing to disclose.

Coauthor(s)

Rachel E Gibbs, MD Candidate, Ben Gurion University Medical School for International Health, Israel

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John W King, MD, Professor of Medicine, Chief, Section of Infectious Diseases, Director, Viral Therapeutics Clinics for Hepatitis, Louisiana State University School of Medicine in Shreveport; Consultant in Infectious Diseases, Overton Brooks Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Disclosure: Nothing to disclose.

Additional Contributors

George Kurdgelashvili, MD, Clinical Associate Professor of Medicine, Department of Medicine, University of Oklahoma College of Medicine; Assistant Chief of Medical Service, Director of Diagnostic Center Clinic, Chair of Infection Prevention and Control Committee, Attending Physician, Infectious Diseases Section, Oklahoma City Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

Thomas J Marrie, MD, Dean of Faculty of Medicine, Dalhousie University Faculty of Medicine, Canada

Disclosure: Nothing to disclose.

References

  1. Bush LM, Vazquez-Pertejo MT. Nocardiosis. Porter RE. The Merck Manual of Diagnosis and Therapy. Rahway, NJ: Merck & Co Inc; March 2023.
  2. CDC. Nocardiosis. US Centers for Disease Control and Prevention. Available at https://www.cdc.gov/nocardiosis/about/index.html. May 2, 2024; Accessed: December 30, 2024.
  3. Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin Proc. 2012 Apr. 87(4):403-7. [View Abstract]
  4. Euzeby Jean P. List of prokaryotic names with standing in nomenclature. www.bacterio.net/. Available at https://www.bacterio.net/-allnamesmr.html. Accessed: December 30, 2024.
  5. Beaman BL, Beaman L. Nocardia species: host-parasite relationships. Clin Microbiol Rev. 1994 Apr. 7(2):213-64. [View Abstract]
  6. Smego RA Jr, Moeller MB, Gallis HA. Trimethoprim-sulfamethoxazole therapy for Nocardia infections. Arch Intern Med. 1983 Apr. 143(4):711-8. [View Abstract]
  7. Lavalard E, Guillard T, Baumard S, Grillon A, Brasme L, Rodríguez-Nava V, et al. Brain abscess due to Nocardia cyriacigeorgica simulating an ischemic stroke. Ann Biol Clin (Paris). 2013 Jun 1. 71(3):345-348. [View Abstract]
  8. Paige EK, Spelman D. Nocardiosis: 7-year experience at an Australian tertiary hospital. Intern Med J. 2019 Mar. 49 (3):373-379. [View Abstract]
  9. Steinbrink J, Leavens J, Kauffman CA, Miceli MH. Manifestations and outcomes of nocardia infections: Comparison of immunocompromised and nonimmunocompromised adult patients. Medicine (Baltimore). 2018 Oct. 97 (40):e12436. [View Abstract]
  10. Uttamchandani RB, Daikos GL, Reyes RR, Fischl MA, Dickinson GM, Yamaguchi E, et al. Nocardiosis in 30 patients with advanced human immunodeficiency virus infection: clinical features and outcome. Clin Infect Dis. 1994 Mar. 18 (3):348-53. [View Abstract]
  11. Boiron P, Locci R, Goodfellow M, et al. Nocardia, nocardiosis and mycetoma. Med Mycol. 1998. 36 Suppl 1:26-37. [View Abstract]
  12. Castro JG, Espinoza L. Nocardia species infections in a large county hospital in Miami: 6 years experience. J Infect. 2007 Apr. 54(4):358-61. [View Abstract]
  13. Filice GA. Nocardiosis in persons with human immunodeficiency virus infection, transplant recipients, and large, geographically defined populations. J Lab Clin Med. 2005 Mar. 145(3):156-62. [View Abstract]
  14. Hui CH, Au VW, Rowland K, Slavotinek JP, Gordon DL. Pulmonary nocardiosis re-visited: experience of 35 patients at diagnosis. Respir Med. 2003 Jun. 97(6):709-17. [View Abstract]
  15. Kilincer C, Hamamcioglu MK, Simsek O, et al. Nocardial brain abscess: review of clinical management. J Clin Neurosci. 2006 May. 13(4):481-5. [View Abstract]
  16. Lederman ER, Crum NF. A case series and focused review of nocardiosis: clinical and microbiologic aspects. Medicine (Baltimore). 2004 Sep. 83(5):300-13. [View Abstract]
  17. Lerner PI. Nocardiosis. Clin Infect Dis. 1996 Jun. 22(6):891-903; quiz 904-5. [View Abstract]
  18. Matulionyte R, Rohner P, Uckay I, et al. Secular trends of nocardia infection over 15 years in a tertiary care hospital. J Clin Pathol. 2004 Aug. 57(8):807-12. [View Abstract]
  19. Pintado V, Gomez-Mampaso E, Cobo J, et al. Nocardial infection in patients infected with the human immunodeficiency virus. Clin Microbiol Infect. 2003 Jul. 9(7):716-20. [View Abstract]
  20. Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol. 2003 Oct. 41(10):4497-501. [View Abstract]
  21. Pilsczek FH, Augenbraun M. Mycetoma fungal infection: multiple organisms as colonizers or pathogens?. Rev Soc Bras Med Trop. 2007 Jul-Aug. 40(4):463-5. [View Abstract]
  22. Martinez Tomas R, Menendez Villanueva R, Reyes Calzada S, et al. Pulmonary nocardiosis: risk factors and outcomes. Respirology. 2007 May. 12(3):394-400. [View Abstract]
  23. Rosman Y, Grossman E, Keller N, Thaler M, Eviatar T, Hoffman C, et al. Nocardiosis: A 15-year experience in a tertiary medical center in Israel. Eur J Intern Med. 2013 May 29. [View Abstract]
  24. Özen Y, Dokuzoguz B, Mumcuoglu I, Çelikbas AK, Karahan ZC, Özbay BO. Disseminated Nocardia farcinica infection presenting as a paravertebral abscess in a patient with systemic lupus erythematosus. Indian J Pathol Microbiol. 2019 Apr-Jun. 62 (2):329-331. [View Abstract]
  25. Baek JO, Kim JS, Lee SK, Jeong JH, Lee MJ, Seo IH. Two cases of primary cutaneous nocardiosis caused by intralesional injection. Dermatol Ther. 2019 Jan. 32 (1):e12775. [View Abstract]
  26. Smego RA Jr, Gallis HA. The clinical spectrum of Nocardia brasiliensis infection in the United States. Rev Infect Dis. 1984 Mar-Apr. 6 (2):164-80. [View Abstract]
  27. Smego RA Jr, Castiglia M, Asperilla MO. Lymphocutaneous syndrome. A review of non-sporothrix causes. Medicine (Baltimore). 1999 Jan. 78 (1):38-63. [View Abstract]
  28. Inamadar AC, Palit A, Peerapur BV, Rao SD. Sporotrichoid nocardiosis caused by Nocardia nova in a patient infected with human immunodeficiency virus. Int J Dermatol. 2004 Nov. 43 (11):824-6. [View Abstract]
  29. Ma F, Kang M, Liao YH, Lee GZ, Tang Q, Tang C, et al. Nocardial spinal epidural abscess with lumbar disc herniation: A case report and review of literature. Medicine (Baltimore). 2018 Dec. 97 (49):e13541. [View Abstract]
  30. Hudson JD, Danis RP, Chaluvadi U, Allen SD. Posttraumatic exogenous Nocardia endophthalmitis. Am J Ophthalmol. 2003 Jun. 135 (6):915-7. [View Abstract]
  31. Haripriya A, Lalitha P, Mathen M, Prajna NV, Kim R, Shukla D, et al. Nocardia endophthalmitis after cataract surgery: clinicomicrobiological study. Am J Ophthalmol. 2005 May. 139 (5):837-46. [View Abstract]
  32. Eggink CA, Wesseling P, Boiron P, Meis JF. Severe keratitis due to Nocardia farcinica. J Clin Microbiol. 1997 Apr. 35 (4):999-1001. [View Abstract]
  33. Chaidaroon W, Tantayakom T. Nocardia keratitis in a human immunodeficiency virus patient. Jpn J Ophthalmol. 2004 May-Jun. 48 (3):272-5. [View Abstract]
  34. Wenger PN, Brown JM, McNeil MM, Jarvis WR. Nocardia farcinica sternotomy site infections in patients following open heart surgery. J Infect Dis. 1998 Nov. 178 (5):1539-43. [View Abstract]
  35. Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis. 2007 May 15. 44(10):1307-14. [View Abstract]
  36. Abreu C, Rocha-Pereira N, Sarmento A, Magro F. Nocardia infections among immunomodulated inflammatory bowel disease patients: A review. World J Gastroenterol. 2015 Jun 7. 21 (21):6491-8. [View Abstract]
  37. Couble A, Rodríguez-Nava V, de Montclos MP, Boiron P, Laurent F. Direct detection of Nocardia spp. in clinical samples by a rapid molecular method. J Clin Microbiol. 2005 Apr. 43 (4):1921-4. [View Abstract]
  38. Blosser SJ, Drake SK, Andrasko JL, Henderson CM, Kamboj K, Antonara S, et al. Multicenter Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Study for Identification of Clinically Relevant Nocardia spp. J Clin Microbiol. 2016 May. 54 (5):1251-8. [View Abstract]
  39. Lebeaux D, Freund R, van Delden C, Guillot H, Marbus SD, Matignon M, et al. Outcome and Treatment of Nocardiosis After Solid Organ Transplantation: New Insights From a European Study. Clin Infect Dis. 2017 May 15. 64 (10):1396-1405. [View Abstract]
  40. Simpson GL, Stinson EB, Egger MJ, Remington JS. Nocardial infections in the immunocompromised host: A detailed study in a defined population. Rev Infect Dis. 1981 May-Jun. 3 (3):492-507. [View Abstract]
  41. Coussement J, Lebeaux D, van Delden C, Guillot H, Freund R, Marbus S, et al. Nocardia Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study. Clin Infect Dis. 2016 Aug 1. 63 (3):338-45. [View Abstract]
  42. Uhde KB, Pathak S, McCullum I Jr, et al. Antimicrobial-resistant nocardia isolates, United States, 1995-2004. Clin Infect Dis. 2010 Dec 15. 51(12):1445-8. [View Abstract]
  43. Brown-Elliott BA, Biehle J, Conville PS, Cohen S, Saubolle M, Sussland D. Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey. J Clin Microbiol. 2012 Mar. 50(3):670-2. [View Abstract]
  44. Minero MV, Marin M, Cercenado E, Rabadan PM, Bouza E, Munoz P. Nocardiosis at the turn of the century. Medicine (Baltimore). 2009 Jul. 88(4):250-61. [View Abstract]

High-power microscopic appearance of Nocardia. Image courtesy of CDC.

Photomicrograph of tissue biopsy stained with Gomori methenamine silver demonstrating acute inflammatory response and organisms compatible with Nocardia.

Plain chest radiograph in a patient with nocardiosis. Image courtesy of Applied Radiology, Anderson Publishing, LTD.

Chest CT scan in a patient with pleuropulmonary nocardiosis. Image courtesy of Applied Radiology, Anderson Publishing, LTD.

Brain CT scan in a patient with nocardial brain abscess. Image courtesy of Applied Radiology, Anderson Publishing, LTD.

High-power microscopic appearance of Nocardia. Image courtesy of CDC.

Photomicrograph of tissue biopsy stained with Gomori methenamine silver demonstrating acute inflammatory response and organisms compatible with Nocardia.

Plain chest radiograph in a patient with nocardiosis. Image courtesy of Applied Radiology, Anderson Publishing, LTD.

Chest CT scan in a patient with pleuropulmonary nocardiosis. Image courtesy of Applied Radiology, Anderson Publishing, LTD.

Brain CT scan in a patient with nocardial brain abscess. Image courtesy of Applied Radiology, Anderson Publishing, LTD.